{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T09:04:53Z","timestamp":1785315893698,"version":"3.55.0"},"reference-count":21,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Palbociclib and ribociclib are widely used with letrozole as first-line treatment for postmenopausal patients with hormone receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer. Pivotal trials have reported different overall survival signals, but they were not designed as direct comparisons. This study evaluated real-world survival outcomes with these regimens and explored the prognostic performance of a composite clinical-inflammatory risk score. Materials and Methods: This retrospective single-center cohort included 140 postmenopausal patients treated with first-line palbociclib\/letrozole or ribociclib\/letrozole. Overall survival, progression-free survival, best documented response, baseline characteristics, metastatic pattern, and baseline pan-immune-inflammation value were evaluated. The composite risk score assigned one point each for progesterone receptor expression &lt;20%, visceral metastasis, and pan-immune-inflammation value \u2265477.8. Pan-immune-inflammation value was additionally evaluated as a continuous variable. The prognostic performance of the score was assessed using Harrell\u2019s c-index, bootstrap internal validation, and comparison with a parsimonious clinical model. Results: Among 140 patients, 67 received palbociclib\/letrozole and 73 received ribociclib\/letrozole. Median follow-up was 52.3 months. A total of 93 deaths and 118 progression-free survival events occurred. Median overall survival was 36 months with palbociclib\/letrozole and 29 months with ribociclib\/letrozole, with no statistically significant difference between groups (HR, 1.23; 95% CI, 0.82\u20131.86; p = 0.322). Median progression-free survival was 15.4 and 16.4 months, respectively (HR, 1.05; 95% CI, 0.73\u20131.52; p = 0.778). Median overall survival was 34 months for CRS 0\u20131 and 30 months for CRS 2\u20133 (univariable HR, 1.68; 95% CI, 1.11\u20132.54; p = 0.014). The apparent and optimism-corrected c-indices of the score were 0.573 and 0.570, respectively. Addition of the score to the parsimonious clinical model did not significantly improve model fit (likelihood-ratio p = 0.143). Conclusions: No statistically detectable difference in overall survival or progression-free survival between the treatment groups was observed in this cohort. Although grouped CRS was associated with overall survival in univariable analysis, the score showed limited discrimination and no statistically significant incremental prognostic value. These findings remain exploratory and require external validation.<\/jats:p>","DOI":"10.3390\/medicina62081470","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T08:16:52Z","timestamp":1785313012000},"page":"1470","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["First-Line Palbociclib\/Letrozole Versus Ribociclib\/Letrozole in Postmenopausal HR-Positive\/HER2-Negative Metastatic Breast Cancer: A Retrospective Real-World Study and an Exploratory Composite Clinical-Inflammatory Risk Score"],"prefix":"10.3390","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3653-4429","authenticated-orcid":false,"given":"Mert","family":"Tohumcuo\u011flu","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Adana City Training and Research Hospital, University of Health Sciences, Adana 01230, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah Evren","family":"Yeti\u015fir","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Adana City Training and Research Hospital, University of Health Sciences, Adana 01230, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zafer Ufuk","family":"Cinkara","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Adana City Training and Research Hospital, University of Health Sciences, Adana 01230, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4163-917X","authenticated-orcid":false,"given":"Mehmet","family":"T\u00fcrker","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Adana City Training and Research Hospital, University of Health Sciences, Adana 01230, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2994-9191","authenticated-orcid":false,"given":"Alpay","family":"D\u00fc\u015fg\u00fcn","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Adana City Training and Research Hospital, University of Health Sciences, Adana 01230, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5986-5493","authenticated-orcid":false,"given":"Cem","family":"Mirili","sequence":"additional","affiliation":[{"name":"Medical Oncology Clinic, Adana Ortado\u011fu Hospital, Adana 01140, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz","family":"Tazeo\u011flu","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Osmaniye State Hospital, Osmaniye 80010, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tolga","family":"K\u00f6\u015feci","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, \u00c7ukurova University, Adana 01330, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4886-7060","authenticated-orcid":false,"given":"Ali","family":"O\u011ful","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Mersin University, Mersin 33343, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6356-9059","authenticated-orcid":false,"given":"Mahmut","family":"B\u00fcy\u00fck\u015fim\u015fek","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Adana City Training and Research Hospital, University of Health Sciences, Adana 01230, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1200\/JCO.21.01392","article-title":"Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update","volume":"39","author":"Burstein","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1200\/JCO.23.00137","article-title":"Overall survival with palbociclib plus letrozole in advanced breast cancer","volume":"42","author":"Slamon","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1903765","article-title":"Overall survival with ribociclib plus endocrine therapy in breast cancer","volume":"381","author":"Im","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1911149","article-title":"Overall survival with ribociclib plus fulvestrant in advanced breast cancer","volume":"382","author":"Slamon","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1002\/ijc.35296","article-title":"Head-to-head comparison of palbociclib and ribociclib in first-line treatment of HR-positive\/HER2-negative metastatic breast cancer with real-world data from the OPAL registry","volume":"156","author":"Thill","year":"2025","journal-title":"Int. J. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.annonc.2025.03.023","article-title":"Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive\/HER2-negative breast cancer patients: Results from the multicenter PALMARES-2 study","volume":"36","author":"Provenzano","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Guliyev, M., Guren, A.K., Ozge, E., Colak, R., Majidova, N., Alkan Sen, G., Safarov, S., Gunalt\u0131l\u0131, M., Fidan, M.C., and Gulturk, I. (2025). The impact of progesterone receptor status on survival outcomes in metastatic breast cancer patients treated with first-line CDK4\/6 inhibitors. Cancers, 17.","DOI":"10.3390\/cancers17040693"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Jia, L., Peng, J., Sun, N., Chen, H., Liu, Z., Zhao, W., Zhang, Q., and Li, L. (2024). Effect of PR status on the prognosis of advanced ER-high HER2-negative breast cancer patients receiving CDK4\/6 inhibitor combined with endocrine as first-line therapy. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-12621-y"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/s41416-020-0894-7","article-title":"The pan-immune-inflammation value is a new prognostic biomarker in metastatic colorectal cancer: Results from a pooled-analysis of the Valentino and TRIBE first-line trials","volume":"123","author":"Guarini","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Qi, X., Qiao, B., Song, T., Huang, D., Zhang, H., Liu, Y., Jin, Q., Yang, M., and Liu, D. (2023). Clinical utility of the pan-immune-inflammation value in breast cancer patients. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1223786"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13058-021-01409-8","article-title":"Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+\/HER2\u2212 metastatic breast cancer in US real-world clinical practice","volume":"23","author":"DeMichele","year":"2021","journal-title":"Breast Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41523-022-00479-x","article-title":"Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+\/HER2\u2212 metastatic breast cancer","volume":"8","author":"Rugo","year":"2022","journal-title":"npj Breast Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"17588359231216095","DOI":"10.1177\/17588359231216095","article-title":"Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozole versus palbociclib plus letrozole as first-line treatment of HR+\/HER2\u2212 advanced breast cancer","volume":"15","author":"Jhaveri","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"104103","DOI":"10.1016\/j.esmoop.2024.104103","article-title":"Comparative overall survival of CDK4\/6 inhibitors plus an aromatase inhibitor in HR+\/HER2\u2212 metastatic breast cancer in the US real-world setting","volume":"10","author":"Rugo","year":"2025","journal-title":"ESMO Open"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"104665","DOI":"10.1016\/j.breast.2025.104665","article-title":"Real-world outcomes with palbociclib, ribociclib, and abemaciclib plus endocrine therapy in HR+\/HER2\u2212 advanced breast cancer: A multicenter retrospective study","volume":"85","author":"Duchnowska","year":"2026","journal-title":"Breast"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/annonc\/mdx797","article-title":"Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases","volume":"29","author":"Turner","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"24761","DOI":"10.1038\/s41598-025-08128-6","article-title":"Predicting the prognosis of breast cancer patients by using pan-immune-inflammation value: A systematic review and meta-analysis","volume":"15","author":"Prasetiyo","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Tinterri, C., Sagona, A., Barbieri, E., Di Maria Grimaldi, S., Jacobs, F., Zambelli, A., Trimboli, R.M., Bernardi, D., Vinci, V., and Gentile, D. (2022). Loco-Regional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancer Patients Undergoing Front-Line Chemotherapy. Cancers, 14.","DOI":"10.3390\/cancers14246237"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/8\/1470\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T08:53:12Z","timestamp":1785315192000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/8\/1470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":21,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["medicina62081470"],"URL":"https:\/\/doi.org\/10.3390\/medicina62081470","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]}}}